Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Aecom (ACM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Aecom — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Aecom trades at $68.02 (market cap $8.69B). The key difference: Aecom is the larger of the two by market cap, and Aecom pays a 1.76% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ACM | |
|---|---|---|
Market Cap | $4.49B | $8.69B |
Sector | Health | Industrials |
52-Week High | $28.06 | $134.35 |
52-Week Low | $20.06 | $66.86 |
Enterprise Value | $3.69B | $10.88B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ACM trades at $67.64, down 0.15% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.53 and P/S of 0.57, while recent earnings beat expectations in Q1 2026. Analyst consensus is bullish with a $98.83 price target, though recent news includes both contract wins and legal investigations.
The outlook for ACM is mixed: strong valuation metrics and recent contract awards support upside potential, but technical weakness and legal scrutiny pose near-term risks. Earnings growth and margin expansion remain key catalysts, while investor sentiment is cautious due to the stock's 21% decline over the past three months.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →
